Actinium Pharmaceuticals showcases its HER3-targeted alpha radiotherapy, ATNM-400, in a Phase 1 study targeting metastatic castration-resistant prostate cancer at the ESMO 2026 conference.
Actinium Pharmaceuticals is advancing its clinical pipeline with the presentation of a first-in-human Phase 1 study for ATNM-400, a HER3-targeted alpha radiotherapy. This development is significant as it targets metastatic castration-resistant prostate cancer, including patient cohorts that have previously undergone PSMA-directed therapy, thereby positioning the drug as a potentially differentiated therapeutic option.
ATNM-400 is a HER3-targeted alpha radiotherapy.
The study focuses on patients with metastatic castration-resistant prostate cancer, including those who have and have not received prior PSMA-directed therapy.
Actinium Pharmaceuticals unveiled first-in-human Phase 1 study results for its HER3-targeted alpha radiotherapy, ATNM-400. The trial focuses on patients with metastatic castration-resistant prostate cancer, including those previously treated with PSMA-directed therapies.
The study evaluates the safety and potential of HER3-targeted alpha radiotherapy in patients with metastatic castration-resistant prostate cancer.